MME and hydrops fetalis: Sacubitril–valsartan, as an angiotensin–neprilysin inhibition agent, has been proven to be superior to enalapril in reducing the risks of cardiovascular death and hospitalization for HF in HF patients with reduced ejection fraction (HFrEF) (McMurray et al., 2014).